LLY News and Press, Eli Lilly and Company From 06/20/24

2024-06-20 08:30:00 ET It can be hard to make the case that a stock which is trading at more than 120 times earnings is still a good buy, and that its growth prospects still look strong enough to justify its current valuation. But that's what I'm going to try to do with Eli Lilly (N...

2024-06-18 13:49:28 ET More on Eli Lilly Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Eli Lilly’s oral...

2024-06-18 13:30:13 ET Eli Lilly’s ( NYSE: LLY ) success with a newer class of diabetes and weight-loss drugs has the potential to be repeated with other products in its research pipeline, healthcare analysts said Tuesday at the Seeking Alpha Investing Summit in New York.... ...

2024-06-18 11:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-18 11:40:36 ET More on S&P 500 Index: This All-Time High Has Me Preparing For Another Summer Pullback Warning Flags For The Stock Market Consumer Survey Shows Rising Bullishness Least shorted S&P 500 stocks in May Mega caps EPS growth ...

2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...

2024-06-18 10:34:48 ET Alphabet Class C ( GOOG ), Mastercard ( MA ) and Walmart ( WMT ) retained the top spots as the least shorted S&P 500 ( SP500 ) stocks in May.... Read the full article on Seeking Alpha For further details see: Least shorted S&P 5...

2024-06-18 05:56:25 ET Summary Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-s...

2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...

2024-06-17 09:13:40 ET Summary Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a market dominated by Novo Nordisk and Eli Lilly. ...